Astrana Health (NASDAQ:ASTH - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37), Zacks reports. The company had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Astrana Health updated its FY 2025 guidance to EPS.
Astrana Health Stock Performance
Shares of NASDAQ:ASTH traded up $1.10 during trading on Monday, hitting $26.48. 627,541 shares of the stock were exchanged, compared to its average volume of 242,166. Astrana Health has a 1-year low of $23.12 and a 1-year high of $63.20. The company has a market capitalization of $1.49 billion, a price-to-earnings ratio of 20.37, a price-to-earnings-growth ratio of 1.37 and a beta of 1.20. The company's fifty day simple moving average is $34.84 and its 200-day simple moving average is $44.46. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91.
Analyst Ratings Changes
A number of analysts have issued reports on the company. Macquarie raised Astrana Health to a "hold" rating in a report on Monday, December 16th. Truist Financial lowered their target price on Astrana Health from $59.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, January 13th. Stifel Nicolaus lowered their target price on Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, February 20th. Finally, Robert W. Baird lowered their target price on Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a report on Monday. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $58.40.
Read Our Latest Stock Report on ASTH
About Astrana Health
(
Get Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Recommended Stories
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
